Association between the Interleukin-17A -197G>A (rs2275913) Polymorphism and Risk of Digestive Cancer

  • Duan, Yin (Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University) ;
  • Shi, Ji-Nan (Department of Medical Oncology, Zhejiang Hospital) ;
  • Pan, Chi (Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University) ;
  • Chen, Hai-Long (Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University) ;
  • Zhang, Su-Zhan (Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University)
  • Published : 2014.11.28


Interleukin-17A (IL-17A) is a multifunctional cytokine which plays a crucial role in the initiation and progression of cancer. To date, several studies have investigated associations between IL-17A -197G>A (rs2275913) polymorphism and digestive cancer risk, but the results remain conflicting. We here aimed to confirm the role of this single nucleotide polymorphism (SNP) in susceptibility to digestive cancer through a systemic review and meta-analysis. Ten eligible case-control studies were identified by searching electronic databases, involving 3,087 cases and 3,815 controls. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were used to estimate the strength of the association. The results of overall analyses indicated that the variant A allele was associated with an increased risk of digestive cancer (AA vs GG: OR=1.51, 95%CI=1.18-1.93; AA vs GG+GA: OR=1.45, 95%CI=1.12-1.87; A vs G: OR=1.21, 95%CI=1.05-1.39). In subgroup analysis stratified by specific cancer type, elevated risk among studies of gastric cancer was found (AA vs GG: OR=1.68, 95%CI=1.24-2.28; AA vs GG+GA: OR=1.62, 95%CI=1.16-2.26; A vs G: OR=1.23, 95%CI=1.04-1.46). According to ethnicity, there was evidence in the Asian populations for an association between this polymorphism and cancer risk (GA vs GG: OR=1.19, 95%CI=1.05-1.36; AA vs GG: OR=1.56, 95%CI=1.15-2.12; AA+GA vs GG: OR=1.28, 95%CI=1.13-1.44; AA vs GG+GA: OR=1.42, 95%CI=1.01-2.00; A vs G: OR=1.24, 95%CI=1.08-1.44), while in the Caucasian populations an association was found in the recessive model (AA vs GG+GA: OR=1.62, 95%CI=1.17-2.24). In conclusion, the results of this meta-analysis suggest that the IL-17A -197G>A polymorphism contributes to an increased risk of human digestive cancer, both in the Asian and Caucasian populations and especially for gastric cancer.


  1. Alexandrakis MG, Pappa CA, Miyakis S, et al (2006). Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. Eur J Intern Med, 17, 412-6.
  2. Arisawa T, Tahara T, Shiroeda H, et al (2012). Genetic polymorphisms of IL17A and pri-microRNA-938, targeting IL17A 3'-UTR, influence susceptibility to gastric cancer. Hum Immunol, 73, 747-52.
  3. Bazzi MD, Sultan MA, Al Tassan N, et al (2011). Interleukin 17A and F and asthma in Saudi Arabia: gene polymorphisms and protein levels. J Investig Allergol Clin Immunol, 21, 551-5.
  4. Bettelli E, Carrier Y, Gao W, et al (2006). Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature, 441, 235-8.
  5. Bidwell J, Keen L, Gallagher G, et al (1999). Cytokine gene polymorphism in human disease: on-line databases. Genes Immun, 1, 3-19.
  6. Bredberg A (2011). Cancer: more of polygenic disease and less of multiple mutations? A quantitative viewpoint. Cancer, 117, 440-5.
  7. Breslow NE, Day NE (1987). Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ, 1-406.
  8. Chen J, Deng Y, Zhao J, et al (2010). The polymorphism of IL-17 G-152A was associated with childhood asthma and bacterial colonization of the hypopharynx in bronchiolitis. J Clin Immunol, 30, 539-45.
  9. Dai W, Zhou Q, Tan X, et al (2014). IL-17A (-197G/A) and IL-17F (7488T/C) gene polymorphisms and cancer risk in Asian population: a meta-analysis. Onco Targets Ther, 7, 703-11.
  10. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  11. Doroudchi M, Pishe ZG, Malekzadeh M, et al (2013). Elevated serum IL-17A but not IL-6 in glioma versus meningioma and schwannoma. Asian Pac J Cancer Prev, 14, 5225-30.
  12. Espinoza JL, Takami A, Nakata K, et al (2011). A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS One, 6, 26229.
  13. Gonzalez-Hormazabal P, Musleh M, Bustamante M, et al (2014). Role of cytokine gene polymorphisms in gastric cancer risk in Chile. Anticancer Res, 34, 3523-30.
  14. Haber M (1981). Exact significance levels of goodness-of-fit tests for the Hardy-Weinberg equilibrium. Hum Hered, 31, 161-6.
  15. Harrington LE, Hatton RD, Mangan PR, et al (2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 6, 1123-32.
  16. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
  17. Hoeijmakers JH (2001). Genome maintenance mechanisms for preventing cancer. Nature, 411, 366-74.
  18. Kaabachi W, ben Amor A, Kaabachi S, et al (2014). Interleukin-17A and -17F genes polymorphisms in lung cancer. Cytokine, 66, 23-9.
  19. Karin M (2006). Nuclear factor-kappaB in cancer development and progression. Nature, 441, 431-6.
  20. Kato T, Furumoto H, Ogura T, et al (2001). Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun, 282, 735-8.
  21. Kawaguchi M, Adachi M, Oda N, et al (2004). IL-17 cytokine family. J Allergy Clin Immunol, 114, 1265-73.
  22. Kolls JK, Linden A (2004). Interleukin-17 family members and inflammation. Immunity, 21, 467-76.
  23. Kuper H, Adami HO, Trichopoulos D (2000). Infections as a major preventable cause of human cancer. J Intern Med, 248, 171-83.
  24. Kutikhin AG, Yuzhalin AE, Volkov AN, et al (2014). Correlation between genetic polymorphisms within IL-1B and TLR4 genes and cancer risk in a Russian population: a case-control study. Tumour Biol, 35, 4821-30.
  25. Li N, Zhu Q, Li Z, et al (2014). IL17A gene polymorphisms, serum IL-17A and IgE levels, and hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Mol Carcinog, 53, 447-57.
  26. Lin WW, Karin M (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest, 117, 1175-83.
  27. Liu J, Duan Y, Cheng X, et al (2011). IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun, 407, 348-54.
  28. Liu XK, Lin X, Gaffen SL (2004). Crucial role for nuclear factor of activated T cells in T cell receptor-mediated regulation of human interleukin-17. J Biol Chem, 279, 52762-71.
  29. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  30. Moseley TA, Haudenschild DR, Rose L, et al (2003). Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev, 14, 155-74.
  31. Mustapha MA, Shahpudin SN, Aziz AA, et al (2012). Risk modification of colorectal cancer susceptibility by interleukin-8 -251T>A polymorphism in Malaysians. World J Gastroenterol, 18, 2668-73.
  32. Numasaki M, Fukushi J, Ono M, et al (2003). Interleukin-17 promotes angiogenesis and tumor growth. Blood, 101, 2620-7.
  33. Omrane I, Marrakchi R, Baroudi O, et al (2014). Significant association between interleukin-17A polymorphism and colorectal cancer. Tumour Biol, 35, 6627-32.
  34. Pan XF, Yang SJ, Loh M, et al (2013). Interleukin-10 gene promoter polymorphisms and risk of gastric cancer in a Chinese population: single nucleotide and haplotype analyses. Asian Pac J Cancer Prev, 14, 2577-82.
  35. Qinghai Z, Yanying W, Yunfang C, et al (2014). Effect of interleukin-17A and interleukin-17F gene polymorphisms on the risk of gastric cancer in a Chinese population. Gene, 537, 328-32.
  36. Quan Y, Zhou B, Wang Y, et al (2012). Association between IL17 polymorphisms and risk of cervical cancer in Chinese women. Clin Dev Immunol, 2012, 258293.
  37. Rafiei A, Hosseini V, Janbabai G, et al (2013). Polymorphism in the interleukin-17A promoter contributes to gastric cancer. World J Gastroenterol, 19, 5693-9.
  38. Sterne JA, Gavaghan D, Egger M (2000). Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol, 53, 1119-29.
  39. Straus DS (2013). TNFalpha and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. Mol Cancer, 12, 78.
  40. Wang L, Jiang Y, Zhang Y, et al (2012). Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer. PLoS One, 7, 34400.
  41. Wang M, Zhang Y, Han D, et al (2012). Association between polymorphisms in cytokine genes IL-17A and IL-17F and development of allergic rhinitis and comorbid asthma in Chinese subjects. Hum Immunol, 73, 647-53.
  42. Wang N, Yang J, Lu J, et al (2014). IL-17 gene polymorphism is associated with susceptibility to gastric cancer. Tumour Biol.
  43. Wang S, Liu Z, Wang L, et al (2009). NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol, 6, 327-34.
  44. Wu X, Zeng Z, Chen B, et al (2010). Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer. Int J Cancer, 127, 86-92.
  45. Wu X, Zeng Z, Xu L, et al (2014). Increased expression of IL17A in human gastric cancer and its potential roles in gastric carcinogenesis. Tumour Biol, 35, 5347-56.
  46. Yang L, Sun MJ, Liu JW, et al (2013). IL-6-6331 (T/C, rs10499563) is associated with decreased risk of gastric cancer in Northern Chinese. Asian Pac J Cancer Prev, 14, 7467-72.
  47. Yin J, Wang L, Shi Y, et al (2014). Interleukin 17A rs4711998 A>G polymorphism was associated with a decreased risk of esophageal cancer in a Chinese population. Dis Esophagus, 27, 87-92.
  48. Zhang B, Rong G, Wei H, et al (2008). The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun, 374, 533-7.
  49. Zhang GQ, Han F, Fang XZ, et al (2012). CD4+, IL17 and Foxp3 expression in different pTNM stages of operable non-small cell lung cancer and effects on disease prognosis. Asian Pac J Cancer Prev, 13, 3955-60.
  50. Zhang T, Wang H (2013). Variants of interleukin-16 associated with gastric cancer risk. Asian Pac J Cancer Prev, 14, 5269-73.
  51. Zhao HY, Wang R, Ma W (2014). IL-17A G197A and IL-17F T7488C polymorphisms and cancer risk in Asian populations: a meta-analysis. J BUON, 19, 562-6.
  52. Zhou B, Zhang P, Wang Y, et al (2013). Interleukin-17 gene polymorphisms are associated with bladder cancer in a Chinese Han population. Mol Carcinog, 52, 871-8.
  53. Zhu X, Mulcahy LA, Mohammed RA, et al (2008). IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res, 10, 95.

Cited by

  1. Interferon-γ and Interleukin-10 Gene Polymorphisms are not Predictors of Chronic Hepatitis C (Genotype-4) Disease Progression vol.16, pp.12, 2015,
  2. IL-1β Polymorphism and Expression Associated with Decreased Risk of Gastric Carcinoma: a Case Control Study in the Ethnic Kashmiri Population, India vol.16, pp.5, 2015,
  3. The IL-17A rs2275913 single nucleotide polymorphism is associated with protection to tuberculosis but related to higher disease severity in Argentina vol.7, pp.1, 2017,
  4. Association Between the Interleukin-17 Gene Polymorphism -197G>A and the Risk of Prostate Cancer in a Galician Population pp.1532-2807, 2018,